Lv4
558 积分 2025-06-12 加入
Venetoclax combined with azacitidine in elderly acute myeloid leukemia: A retrospective comparison of 14-day vs 28-day dosing regimens
25天前
已完结
[Real-World Study of 21-Day Venetoclax Plus Azacitidine Regimen in the Treatment of Newly Diagnosed Unfit-Acute Myeloid Leukemia]
25天前
已关闭
Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial
25天前
已关闭
The approach of HMA plus VEN with or without BMT for all patients with AML
25天前
已关闭
Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
25天前
已关闭
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
25天前
已完结
Are you ready for it? VEN-HMA for younger patients with AML
25天前
已关闭
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia
25天前
已完结
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML
25天前
已关闭
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
26天前
已完结
皖公网安备34019202002308
